Understanding the impact of these fusion partners on oncogenic potential is crucial for precision therapy.<h4>Methods</h4>We report a case of a spindle cell tumor harboring an <i>MYH10::RET</i> fusion, which initially responded to anti-RET therapy but relapsed due to an <i>NTRK1</i> fusion. Here, RET is linked to spindle cell neoplasm.